We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > Article > Science & Health

Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research

By Ruairi J Mackenzie

Published: Nov 19, 2020   

Complete the form below and we will email you a PDF version of "Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Making Mushrooms: How Psilocybin Is Extracted and Used in Mental Health Research

Psilocybin’s emergence as a valuable tool for mental health research has been a huge breakthrough for the field. But how do researchers get their hands on this heavily regulated substance? Technology Networks talked to Tim Moore, CEO of Havn Life Sciences, a company that produces psychoactive compounds from plants and fungi, to find out more. Havn Life recently made a donation towards a pioneering study in Germany that will utilize psilocybin in a clinical context.


Ruairi Mackenzie (RM): How is psilocybin produced on a mass scale?

Tim Moore (TM): At present, there is no formal supply chain for the mass production of psilocybin. The fungi grow in nature and have been cultivated historically in the black and gray market. More recently we have seen firms developing synthetic psilocybin, but our business plan is to provide a naturally-derived alternative. Synthetic psilocybin can be expensive and is inconsistent with people’s desire for a plant-based alternative to the pharmaceutical industry. It also often requires the assignment of IP, which can be prohibitive to academics. We are extracting psilocybin from fungi and developing the methods to do so on a mass scale while developing safety profiles and a compound library to support the research going on in this space and move the industry forward.


RM:  Where is the demand for research-grade psilocybin coming from? Is it 
mainly an academic market?

TM: The demand for research-grade psilocybin is growing, and research is the first step that must be taken in order to bring the industry mainstream. It is taking place globally, in both academic institutions and in clinics; there are at least 142 studies taking place globally.  Our goal is to develop the supply chain for this industry, which starts with developing methods for extraction and standardization, to manage quality and scale for current and future needs. Researchers need access to standardized, quality-controlled compounds to conduct successful research and provide reliable data, patients need access to standardized, quality-controlled formulated products to achieve safe and consistent health outcomes and policymakers need researchers to be able to reference reliable data and to set health and safety standards for products.


RM:  You are supporting a study in Germany with MIND Foundation. Could you tell us more about the study and how psilocybin will be used in it?

TM: We are supporting the Psilocybin Depression Study, which is led by principal investigator Prof. Dr. Gerhard Gründer at the Central Institute of Mental Health in Mannheim who is working together with a group at the Charité Universitätsmedizin Berlin and the MIND Foundation. It will focus on investigating the safety and efficacy of psilocybin administered under supportive conditions in a controlled, randomized and double-blind design. This is the kind of study that can pave the way for regulatory approval of this drug for depression treatment. The team expects to achieve significant treatment responses with a therapeutic (25 mg) oral dose of psilocybin in comparison to an active control dose of psilocybin (5 mg) and niacin, which will be used as a placebo. The study will investigate the effect of administering a second therapeutic dose six weeks after the first therapeutic dose. This will be the first clinical study of its kind in Germany since the 1970s. There are 144 patients planned to participate.


RM:  What do you see as the most promising applications for psilocybin and psilocin?

TM: There are so many potential applications that have already shown tremendous promise, including treatment-resistant depression, PTSD, cluster headaches and so many more mental health challenges, including addiction. 



Tim Moore was speaking to Ruairi J Mackenzie, science writer for Technology Networks


Ruairi J Mackenzie

Senior Science Writer

Ruairi started with Technology Networks in January 2018 after completing an undergraduate degree in neuroscience at the University of Edinburgh and a master’s degree in clinical neuroscience from the University of Cambridge. As senior science writer, Ruairi covers a range of scientific news and articles, with a focus on the complexities and curiosities of the brain. Ruairi also looks after search engine optimization (SEO) efforts on Technology Networks and created the site’s podcast, Opinionated Science, in 2020.

 

Like what you just read? You can find similar content on the topic tag shown below.

Psychedelics

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement